Filipendula ulmaria In 1897, Felix Hoffmann created a synthetically altered version of salicin, derived from the species, which caused less digestive upset than pure salicylic acid. The new drug, formally acetylsalicylic acid, was named aspirin by Hoffmann's employer Bayer AG after the old botanical name for meadowsweet, "Spiraea ulmaria". This gave rise to the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). A natural black dye can be obtained from the roots by using a copper mordant. A tea made from "Filipendula ulmaria" flowers or leaves has been used in traditional Austrian herbal medicine for the treatment of rheumatism, gout, infections,
4-Aminosalicylic acid enzymatic activity. PAS was first synthesized by Seidel and Bittner in 1902. It was rediscovered by the Swedish chemist Jörgen Lehmann upon the report that the tuberculosis bacterium avidly metabolized salicylic acid. Lehmann first tried PAS as an oral TB therapy late in 1944. The first patient made a dramatic recovery. The drug proved better than streptomycin, which had nerve toxicity and to which TB could easily develop resistance. In the 1948, researchers at Britain's Medical Research Council demonstrated that combined treatment with streptomycin and PAS was superior to either drug alone, and established the principle of combination therapy for